Learn More About OncoSec

OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)

TAVO Demonstration AACR 2019 Poster

Key Opinion Leader Symposium Webcast

Corporate Presentation

Clinical trials of today may power
the medical advances of tomorrow.

Learn more about our current clinical trials:

Advanced Melanoma Triple Negative Breast Cancer

Spotlight

Nature Gene Therapy: Characterization of abscopal effects of intratumoral electroporation-mediated IL-12 gene therapy

Immuno-Oncology News: TAVO reverses resistance to PD-1 inhibitors in metastatic melanoma, phase 2b trial suggests

Health Professionals Radio: President and CEO Dan O’Connor discusses late-stage studies in melanoma and TNBC.

News & Events

May 23, 2019

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

May 22, 2019

OncoSec Medical Incorporated Prices $11,000,000 Public Offering

May 22, 2019

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

May 21, 2019

OncoSec Medical Incorporated Announces Proposed Public Offering

Tavokinogene Telseplasmid “TAVO”

Designed to take the fight directly to the tumor

We are investigating the potential for our lead product candidate, TAVO, through the intratumoral administration of IL-12, to stimulate systemic immune response and to become an innovative and potentially transformative therapy option for the treatment of cancer.

Learn More